GLP1R and obesity disorder: Orforglipron (also known as LY3502970 or OWL833), a new oral GLP-1 analog, is currently under investigation in phase 1 and 2 clinical trials [38,39] in patients with diabetes or obesity and who are overweight and have weight-related comorbidities (including MAFLD) [40].